The implantable sensor is placed under the skin in an office by a healthcare provider. Depending on the exact device, your sensor might be inserted in your abdomen or arm. An adhesive patch goes over ...

DexCom recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose Monitoring System ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...

“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 ...

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered ...

ESP32-based portable blood glucose visualisation device with e-ink display. Utilizes Dexcom API, BME280, and VCNL4040 sensors. Developed in C++ for low power, long battery life.